Goodwin Biotechnology
- Company typePrivate
- Founded1991
- HeadquartersPlantation, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Goodwin Biotechnology does
Goodwin Biotechnology, now operating as GBI Biomanufacturing, is a full-service biopharmaceutical contract development and manufacturing organization (CDMO) founded in 1991 and headquartered in Plantation, Florida. The company delivers an integrated platform branded as the Single-Source Solution™, which spans the full biologics manufacturing value chain: upstream cell culture development, cGMP cell banking, downstream purification, cGMP clinical and commercial manufacturing, bioconjugation, aseptic fill and finish, stability testing, and analytical method development and characterization. These core manufacturing services are wrapped with regulatory/CMC support, project management, manufacturing strategy consulting, and quality systems built on a Quality by Design framework.
The company serves biopharmaceutical companies — particularly those developing complex biologic therapeutics, biosimilars, and targeted-delivery biologics requiring bioconjugation — by reducing manufacturing risk and providing integrated development-through-commercial capabilities under one roof. Its go-to-market is direct B2B enterprise sales, supported by participation in industry events (BIO International Convention, BioFlorida) and content marketing. Revenue mechanics are fee-for-service project-based contracts, with pricing determined per engagement; no public rate cards exist. The company is privately held with 51–100 employees, has raised at least $20.7M in disclosed funding (April 2019), and is currently expanding its Broward County facility (May 2026) to add stem cell production capacity targeting Florida's regenerative medicine market.
Goodwin Biotechnology firmographics
Firmographics- Name
- Goodwin Biotechnology
- Legal name
- Goodwin Biotechnology Inc.
- Website
- https://goodwinbio.com
- Company type
- Private
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Goodwin Biotechnology industry classification
Industry- Product category
- Biopharmaceutical Contract Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Goodwin Biotechnology is headquartered
LocationHeadquarters
- HQ city
- Plantation
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Goodwin Biotechnology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Fee-for-service contract manufacturing model providing preclinical, clinical, and commercial manufacturing services for biopharmaceutical companies. Revenue generated through project-based engagements across development and manufacturing phases.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Goodwin Biotechnology product offering
Product offeringCore offering
Goodwin Biotechnology, operating as GBI Biomanufacturing, is a full-service biopharmaceutical contract development and manufacturing organization (CDMO) that delivers integrated biologics manufacturing services from upstream cell culture development through cGMP clinical and commercial manufacturing, bioconjugation, aseptic fill and finish, stability testing, and analytical characterization. Its Single-Source Solution platform combines development, manufacturing, and project support under one roof for biotech and pharma clients producing complex biologic therapeutics, biosimilars, and regenerative medicine products.
Product overview
GBI (formerly Goodwin Biotechnology) is a full-service biopharmaceutical CDMO (Contract Development and Manufacturing Organization) based in Florida that offers a unified platform called Single-Source Solution™. The platform integrates multiple manufacturing services including: Upstream Processing Cell Culture Development, cGMP Cell Banking, DSP Purification Development, cGMP Clinical & Commercial Manufacturing, Bioconjugation, Aseptic Fill & Finish, Stability Testing, and Analytical Method Development/Assay Verification/Characterization. These core manufacturing services are supported by ancillary services including Manufacturing Strategy Development, Project Management, Regulatory & CMC Support, Quality Control & Quality Assurance, and Biomanufacturing Planning. The company focuses on eliminating manufacturing risk for companies developing complex biologic therapeutics, with applications in bioconjugation (biosimilars) and complex biologics.
Differentiator
Problem solved
Functional benefit
Products and services
- Upstream Processing Cell Culture Development
Companies that use Goodwin Biotechnology
Customer profileSegments2 records
Ideal customer profiles1 record
Goodwin Biotechnology technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Goodwin Biotechnology partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
Goodwin Biotechnology competitors and assessment
Company assessmentBroad incumbents
- Lonza: World's largest biologics CDMO with comprehensive mammalian, microbial, and cell therapy capabilities. Competes with GBI across all biologics CDMO service lines but at vastly greater scale.
- Samsung Biologics: Mega-scale biologics CDMO with very large single-site commercial manufacturing capacity. Competes with GBI for outsourced biologics manufacturing but with materially greater capacity and pricing leverage.
- WuXi Biologics: Global biologics CDMO offering end-to-end development and manufacturing including bioconjugation. Comparable service stack to GBI but with much larger global capacity and broader geographic footprint.
- Catalent (Novo Holdings): Large CDMO with biologics manufacturing and fill-finish capabilities. Overlaps with GBI in fill-finish and clinical manufacturing, though Catalent operates across broader modalities and modalities.
- Thermo Fisher Scientific (CDMO services): Operates large-scale biologics and viral vector CDMO services through its Patheon pharma services business. Competes with GBI in clinical and commercial biologics manufacturing at significantly larger scale.
- FUJIFILM Diosynth Biotechnologies: Large-scale global biologics CDMO offering cell culture, microbial, and gene therapy manufacturing. Comparable service categories to GBI but at meaningfully greater scale and geographic footprint.
Direct peers
- AGC Biologics: Global biologics CDMO with mammalian and microbial manufacturing, bioconjugation, and fill-finish capabilities. Comparable to GBI across the integrated biologics CDMO service stack, though operating at larger scale.
- KBI Biopharma: Mid-sized biologics CDMO offering cell line development, process development, cGMP manufacturing, and analytical services. Highly comparable to GBI in scale, biologics focus, and integrated service model.
- Cytovance Biologics: U.S.-based biologics CDMO providing microbial and mammalian cell culture manufacturing, purification, and aseptic fill-finish. Closely comparable to GBI in services, customer base, and mid-market positioning.
Emerging players
- BioReliance (Merck KGaA / MilliporeSigma): Provides biopharmaceutical testing, biosafety, and contract manufacturing services. Comparable to GBI in serving biologics developers, though with greater emphasis on testing and characterization services.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Goodwin Biotechnology social profiles
Digital presenceGoodwin Biotechnology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Goodwin Biotechnology leadership team
Management profileNumber of profiles
Profiles4 records
Goodwin Biotechnology funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Goodwin Biotechnology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Goodwin Biotechnology
What does Goodwin Biotechnology do?
Goodwin Biotechnology, operating as GBI Biomanufacturing, is a full-service biopharmaceutical contract development and manufacturing organization (CDMO) that delivers integrated biologics manufacturing services from upstream cell culture development through cGMP clinical and commercial manufacturing, bioconjugation, aseptic fill and finish, stability testing, and analytical characterization. Its Single-Source Solution platform combines development, manufacturing, and project support under one roof for biotech and pharma clients producing complex biologic therapeutics, biosimilars, and regenerative medicine products.
Is Goodwin Biotechnology a public or private company?
Goodwin Biotechnology is a private company. It is classified as unknown and is currently operating.
When was Goodwin Biotechnology founded?
Goodwin Biotechnology was founded in 1991. It employs 51 to 100 people.
Where is Goodwin Biotechnology based?
Goodwin Biotechnology is headquartered in Plantation, United States, in the North America region.
How does Goodwin Biotechnology make money?
One revenue line is on record: contract Manufacturing Services.
Who are Goodwin Biotechnology's main competitors?
Broad incumbents on record are Lonza, Samsung Biologics, WuXi Biologics, Catalent (Novo Holdings), Thermo Fisher Scientific (CDMO services) and FUJIFILM Diosynth Biotechnologies. Direct peers are AGC Biologics, KBI Biopharma and Cytovance Biologics. BioReliance (Merck KGaA / MilliporeSigma) is listed as an emerging player.
Does Goodwin Biotechnology have an API?
No public API is recorded for Goodwin Biotechnology.
What industry is Goodwin Biotechnology in?
Goodwin Biotechnology's product category is Biopharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325414 and its SIC code is 8731.